1.3 C
New York
Tuesday, January 31, 2023

Fate Therapeutics Inc. (NASDAQ: FATE) May Be Attracting Institutional Investments

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Fate Therapeutics Inc. (FATE) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.10, or -1.75%, to $5.62. The Fate Therapeutics Inc. has recorded 69,124 volume in the after hours trading session. Recently, Yahoo Finance discussed the stock, revealing that Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Stocks Info

Fate Therapeutics Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $5.72 and fluctuated between $5.78 as its day high and $5.32 as its day low. The current market capitalization of Fate Therapeutics Inc. is $1.44B. A total of 3.92 million shares were traded on the day, compared to an average of 2.90M shares.

Insider Activity

Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, FATE has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 31 BUYs and 35 SELLs from insiders. Insiders purchased 575,818 shares during that period but sold 267,330.

In the most recent transaction, Valamehr Bahram sold 10,917 shares of FATE for 5.24 per share on Jan 10. After the transaction, the Chief R&D Officer now owns 168,917 company shares. In a previous transaction on Jan 10, Wolchko J Scott sold 45,907 shares at 5.24 per share. FATE shares that President and CEO owns now total 385,639.

Among the insiders who sold shares, Plavsic Mark disposed of 3,418 shares on Jan 10 at a per-share price of $5.24. This resulted in the Chief Technical Officer holding 123,705 shares of FATE after the transaction. In another insider transaction, TAHL CINDY sold 11,553 shares at $5.24 per share on Jan 10. Company shares held by the General Counsel and Secretary now total 177,598.

Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for FATE in the last 3 months, the mean price target is $15.11 with high estimates of $115.00 and low estimates of $4.00. In terms of 52-week highs and lows, FATE has a high of $49.51 and a low of $4.02.

As of this writing, FATE has an earnings estimate of -$0.89 per share for the current quarter. EPS was calculated based on a consensus of 22 estimates, with a high estimate of -$0.77 per share and a lower estimate of -$1.06. The company reported an EPS of -$0.68 in the last quarter, which was 10.50% higher than expectations of -$0.76.

Balance Sheet Annually/Quarterly

A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information.

Analysts Opinion

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 24 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for FATE is Sell with a score of 3.50. A total of 7 analysts rated the stock as Buy while 1 rated it as Overweight while 14 rated it as Hold. Among the other participants, 1 thought the stock was Underweight and 1 thought it should be Sold.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles